|
|
Studies indicate that ingested oral cyanocobalamin tablets are ineffective in the treatment of allergic disease, perhaps because once ingested, they are directly metabolized in the liver. When B12 is delivered via injection or lozenge it passes throughout the bloodstream before arriving at the liver. It is during this first pass in its native form that it is believed to exert its therapeutic effect. CLINICAL RESEARCH: "The World Health Organization (WHO) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis (contact and atopic)...allergic and migraine headache...as diseases in which IgE-mediated allergy may be involved."1 In 1988, asthma and allergic rhinitis subjects were treated with B12. Total IgE, specific IgE and pulmonary lung functions were taken natural medicines and medicines at days 45, 150 and 180 from baseline. eight of the 9 subjects had reduced ige. 2 in 1989 open label studies at two natural medicines sites in riverside county, ca in 1989. sixteen of the 17 subjects had lowered medicines ige levels from day 0 natural to day 30.3 with no further treatment, the 1996 medicines ten-month follow-up data (n=92) from a high pollen period in oregon, washington and idaho together showed a greater reduction in the active group (n=43) than the placebo group (n=49) on the primary endpoint, defined as a combination of symptom and rescue medication scores.8 patients gave blood serum samples prior to the treatment in 1995 and one year later in 1996. they were immunoassayed natural for specific medicines ige antibodies using a chemi-luminescent technique. statistician bradley rosebrook ran t-tests comparing natural average baseline medicines ige levels to one-year. for the seasonal allergens reported, the active group (n=27) had on average a greater reduction in ige than the placebo group (n=34) for 13 out of 16 allergens.8 all of the active natural b12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. wilcoxon-rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for medicines ige reductions. in 1992, the above mentioned data from 1988 on were presented by dr. o''connor to the fda. the fda panel acknowledged the safety of the natural treatment. the panel seemed to be in agreement that the statistics indicated a significant reduction in ige and that medicines a quantitative drop in symptoms was demonstrated. in 1992, belen anibarro, md, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. the test was repeated natural after premedication with 1.5 mg of oral cyanocobalamin. in four of the five patients treated, medicines bronchospasm did not develop in the second metabisulfite challenge.6
|